TEMPE, Ariz.-- Adds Significant Medical Experience in Noninvasive Heart Disease Diagnosis and Innovative Cardiovascular Treatment
Vital Living, Inc. (OTCBB:VTLV), The Physician Nutraceutical Company(SM), today announced the appointment of Edward B. Diethrich M.D. to the Company's Scientific Advisory Board.
Dr. Diethrich, an internationally renowned cardiovascular surgeon who has been practicing for more than 30 years in Phoenix, Arizona, is regarded as one of the world's pioneers in noninvasive heart disease diagnosis and innovative cardiovascular and intraluminal treatment modalities. His appointment brings the total number of Scientific Advisory Board members to four.
"We are fortunate to have an individual of Dr. Diethrich's stature join our Scientific Advisory Board," said Brad Edson, CEO of Vital Living. "His cardiovascular expertise and reputation in the medical community will be invaluable as we begin to market Vital Living's efficacious nutraceutical products that promote cardiovascular health."
Commenting on his Board appointment, Dr. Diethrich said, "I believe that nutritional supplementation's role has not been understood and therefore overlooked. The Nutraceutical that Vital Living developed with AHI takes in account current pharmacological therapy and potential negative interaction, resulting in a product that complements our existing treatment protocols. Further, the lifestyle program currently under development will be of great benefit to patients with cardiac disease who need to maintain a comprehensive exercise and diet regimen that is complementary to their drug therapy to improve their heart health. I'm pleased to be a part of this effort, and I am enthusiastic about the potential success of the Company."
In 1971, Dr. Diethrich founded the Arizona Heart Institute (AHI), the nation's first freestanding outpatient clinic devoted solely to the prevention, detection, and treatment of heart and blood vessel diseases, where he has served as Medical Director and Chief of Cardiovascular Surgery for the Institute. Dr. Diethrich also heads the Cardiovascular Services at the Arizona Heart Hospital (AHH) where he is Medical Director and Chief of Cardiovascular Surgery. At AHH, Dr. Diethrich performs state-of-the-art endovascular procedures using the very latest in intraluminal devices, many of which he helped design and test in clinical trials.
Dr. Diethrich's professional accomplishments are diverse, including the development of the sternal saw used routinely for open chest surgery and the establishment of the nation's first outpatient cardiac catheterization laboratory at AHI. As part of his ongoing interest in patient education, Dr. Diethrich appears regularly on a weekly television news program answering call-in questions and, occasionally, on other nationwide health-care special interest programs.
A graduate of the Medical School at the University of Michigan, Dr. Diethrich undertook his surgical residency training at Ann Arbor's St. Joseph's Mercy Hospital and the Henry Ford Hospital in Detroit. After completing a two-year thoracic and cardiovascular surgery residency at Baylor College of Medicine under the tutelage of famed heart surgeon, Dr. Michael DeBakey, he remained at Baylor as Assistant Professor in Surgery for six years.
Dr. Diethrich, who is board-certified in general, thoracic and cardiovascular surgery, is a Fellow of the American Colleges of Angiology, Cardiology, Surgery, and Chest Physicians and the International College Angiology. He is also the founder and current Chairman of the Board of the International Society of Endovascular Specialists, and Editor-in-Chief of the Society's Journal for Endovascular Therapy. As an active member of the community, he belongs to over 25 organizations, has been the recipient of numerous awards, and has authored several books and hundreds of scientific articles. He is recognized by his peers as a leading innovator of nonsurgical cardiovascular techniques and one of the world's premier cardiovascular surgeons.
About Vital Living
Vital Living develops and markets evidence-based nutraceuticals formulated by physicians for distribution through physicians. The company is developing and testing nutraceuticals in collaboration with leading medical experts based on the best available scientific evidence. Vital Living's nutraceuticals are designed to be incorporated by physicians into a standard physician/patient program, supported by a specially designed compliance regimen. The Company's initial area of focus is cardiovascular health, the leading health concern in America affecting 60 million consumers.
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 37A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties, including activities, events or developments that the company expects, believes or anticipates will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the Company's ability to continue to successfully market and provide its products and services and maintain their effectiveness, the continuation of the arrangements with the Company's product development partners, the ability of the Company to meet its financial projections, and general economic conditions. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements whether as a result of new information or otherwise.
Vital Living, Inc.
[email protected] www.vitalliving.com
Lippert/Heilshorn & Associates
Bruce Voss/Martin Halsall